Department of Prosthodontics, Dongatn Sacred Heart Hospital, Hallym University, Dongtan, Korea.
Department of Oral Medicine, School of Dentistry, Kyung Hee University, Seoul, Korea.
Int Endod J. 2015 Jul;48(7):705-16. doi: 10.1111/iej.12396. Epub 2014 Nov 5.
To assess whether SIRT1 and VEGF are responsible for tumour necrosis factor-α (TNF-α) and lipopolysaccharide (LPS)-induced angiogenesis and to examine the molecular mechanism(s) of action in human dental pulp cells (HDPCs).
Immortalized HDPCs obtained from Prof. Takashi Takata (Hiroshima University, Japan) were treated with LPS (1 μg mL(-1) ) and TNF-α (10 ng mL(-1) ) for 24 h. mRNA and protein levels were examined by RT-PCR and Western blotting, respectively. Migration and tube formation were examined in human umbilical vein endothelial cells (HUVECs). The data were analysed by one-way anova. Statistical analysis was performed at α = 0.05.
LPS and TNF-α upregulated VEGF and SIRT1 mRNA and protein levels. Inhibition of SIRT1 activity by sirtinol and SIRT1 siRNA or inhibition of the VEGF receptor by CBO-P11 significantly attenuated LPS + TNF-α-stimulated MMPs production in HDPCs, as well as migration and tube formation in HUVECs (P < 0.05). Furthermore, sirtinol, SIRT1 siRNA and CBO-P11 attenuated phosphorylation of Akt, extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK) and the nuclear translocation of NF-κB p65. Pre-treatment with inhibitors of p38, ERK, JNK, PI3K and NF-κB decreased LPS + TNF-α-induced VEGF and SIRT1 expression, MMPs activity in HDPCs and angiogenesis (P < 0.05) in HUVECs.
TNF-α and LPS led to upregulation of VEGF and SIRT1, and subsequent upregulation of MMP-2 and MMP-9 production, and promote angiogenesis via pathways involving PI3K, p38, ERK, JNK and NF-κB. The results suggest that inhibition of SIRT1 and VEGF might attenuate pro-inflammatory mediator-induced pulpal disease.
评估 SIRT1 和 VEGF 是否负责肿瘤坏死因子-α(TNF-α)和脂多糖(LPS)诱导的血管生成,并研究其在人牙髓细胞(HDPC)中的作用机制。
从日本广岛大学 Takashi Takata 教授处获得永生化的 HDPC,用 LPS(1μg/ml)和 TNF-α(10ng/ml)处理 24 小时。分别通过 RT-PCR 和 Western blot 检测 mRNA 和蛋白水平。用人脐静脉内皮细胞(HUVEC)检测迁移和管形成。采用单因素方差分析进行数据分析。统计分析的显著性水平为α=0.05。
LPS 和 TNF-α 上调了 VEGF 和 SIRT1 的 mRNA 和蛋白水平。用 Sirtinol 和 SIRT1 siRNA 抑制 SIRT1 活性,或用 CBO-P11 抑制 VEGF 受体,均可显著减弱 LPS+TNF-α 刺激的 HDPC 中 MMPs 的产生,以及 HUVEC 中的迁移和管形成(P<0.05)。此外,Sirtinol、SIRT1 siRNA 和 CBO-P11 减弱了 Akt、细胞外信号调节激酶(ERK)、p38 和 c-Jun N 末端激酶(JNK)的磷酸化以及核内 NF-κB p65 的易位。用 p38、ERK、JNK、PI3K 和 NF-κB 的抑制剂预处理可降低 LPS+TNF-α 诱导的 HDPC 中 VEGF 和 SIRT1 的表达、MMPs 的活性以及 HUVEC 中的血管生成(P<0.05)。
TNF-α 和 LPS 导致 VEGF 和 SIRT1 的上调,随后 MMP-2 和 MMP-9 的产生上调,并通过涉及 PI3K、p38、ERK、JNK 和 NF-κB 的途径促进血管生成。结果表明,抑制 SIRT1 和 VEGF 可能减轻促炎介质诱导的牙髓疾病。